NovaVive
An immunobiology company

Business Update

June, 2017

Volume 3, Issue 2

Message from the President

Now that we have reached our third anniversary as a company, we are hitting our stride with regard to brand and product recognition. We are being approached by agents in new global jurisdictions who are interested in registering and marketing the MCWF animal health products for us.

At the same time, there is increasing interest in testing our technology in new disease conditions or with modified treatment protocols to assess efficacy. We currently have post-market development projects underway in Canada, Argentina, Serbia and Australia. All of these projects involve Amplimune™, our immunotherapeutic for cattle. Other projects are pending and should begin toward the end of this year.

We are also in contact with regulators in Canada, Australia and New Zealand about adding new products to the list of those already registered. In Canada, we hope to have Settle® approved by the CFIA; in Australia, we are seeking APVMA approval for Amplimune™, and in New Zealand, we are asking the ACVM to consider approving Settle®. For each product, the regulator is asked to review existing data and market information. Sometimes, the regulator asks us to generate additional supportive data.

We are excited about the future animal health opportunities for our immunotherapeutic product line and we appreciate the ongoing support of our customers, distributors, investors, research collaborators and internal team members.

NovaVive Plans for 2017

⇒ Launch Immunocidin® Equine in the U.S. and Canada

⇒ Monitor ongoing post-market development projects in Canada, Argentina, Serbia and Australia

⇒ Launch new post-market development projects

⇒ Obtain new product registrations in Canada, Australia and New Zealand

⇒ Finalize distribution agreements in China, Mexico, UAE, Egypt, Saudi Arabia, Israel and Turkey

Immunocidin® Equine Now Available in the U.S.



In response to veterinarian demand, NovaVive has introduced a new format for Immunocidin® Equine in the U.S. The new 5 mL vial is more appropriate for the commonly required equine dosing. The new format has also been approved by the Canadian regulator, and will soon be available to Canadian veterinarians.

Equine sarcoids are considered to be the most common skin tumors of horses worldwide. They are often found around the eyes, head/face, neck, chest and shoulder, and also at the site of old scars. Sarcoids have been linked to infection of the horse with bovine papillomavirus (BPV). Young to middle-aged horses are most commonly affected by this type of tumor.



Pre-treatment



Post-treatment with Immunocidin® Equine

Results of Canadian Veal Study Presented at ACVIM

Dr. Aleksandar Masic, our Vice-President of Research & Development, presented a Research Report at the 2017 American College of Veterinary Internal Medicine (ACVIM) Forum in National Harbor, Maryland in June. The Research Report summarized the results of a study conducted in a large Canadian veal operation with Amplimune™.

High levels of mortality in dairy calves represent a significant health issue and a major source of economic losses. "Antimicrobials (antibiotics) are traditionally used to reduce mortality on veal and dairy heifer raising operations," said Dr. Masic. "The majority of veal producers introduce antimicrobials to calves immediately on arrival at the farm to prevent disease and again within the first week following arrival. As a result of the abundant use of antimicrobials, high levels of antimicrobial-resistant bacteria have been detected." With antimicrobial resistance becoming of greater concern from both an animal and public health point of view, it is imperative to determine strategies to reduce antimicrobial resistance and use without comprising animal welfare.

In the study presented at the ACVIM Forum, a total of 699 calves age 1-10 days old were randomly assigned into two experimental groups (N=354 MCWF/ Treatment; N=345 Control) and housed in four barns (Delimax, Quebec). Standard farm procedures and metaphylactic therapies (antibiotics and electrolytes) were administered to all animals upon arrival. One dose (1 mL) of MCWF was administered to the Treatment group on the day of arrival and a second dose was administered 7 days later. Calves were monitored daily for adverse events. Data were collected for various clinical conditions in all calves for the duration of the study (154 days). Data for additional antibiotic usage, supplemental treatments (duration of use and costs) and weight of animals were also collected and analyzed.

Key study results are summarized below:

	% Reduction in Treatment Calves vs. Control Calves
Total number of calves requiring treatment	32.3%
Incidence of clinical conditions requiring treatment	66.7%
Volume of antimicrobials and supportive therapies	72.6%
Total number of treatment days	66%
Average number of treatment days per calf	57.9%

Marketing Update

The Company continues to actively promote its products at key practitioner and producer conferences, including:

February, 2017

The North American Veterinary Community Conference—Orlando, FL

London Dairy Congress—London, ON

Eastern Ontario Dairy Days—Kemptville, ON

Southwestern Ontario Diary Symposium—Woodstock, ON

April, 2017

Canadian Dairy XPO—Stratford, ON

Dairy Calf & Heifer Association 2017 Annual Conference—Middleton, WI

Ontario Association of Bovine Practitioners/ Agri-Business Association Spring Meeting—Guelph, ON

September, 2017

American Association of Bovine Practitioners 50th Annual Conference—Omaha, NE

November, 2017

Congrès vétérinaire québécois—Quebec City, PQ

2017 American Association of Equine Practitioners 63rd Annual Convention—San Antonio, TX

like us on facebook

NovaVive Inc.—Equine

NovaVive Inc.—Canine

NovaVive Inc.—Bovine